GRWD5769

Overview

GRWD5769 is an orally potent ERAP1 inhibitor. GRWD5769 regulates the peptide repertoire presented by MHC-I , alters TCR diversity/clonality, reprograms antigen-experienced T cells, induces novel T cell responses, drives tumor cell killing, and alleviates T cell exhaustion. GRWD5769 can be used in the research of advanced solid malignancies, microsatellite-stable colorectal cancer , non-small cell lung cancer , bladder cancer , hepatocellular carcinoma, head and neck squamous cell carcinoma, and cervical cancer .

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Cervical Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Bladder Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > MHC | Products > Signaling Pathways > Aminopeptidase

Product Information

• Catalog No.: HY-184499
• CAS No.: 2420554-24-9
• Molecular Formula: C22H22ClN3O4S
• Molecular Weight: 459.95
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source